Practical Psychopharmacology

Credit

Handouts/Brochure

Speaker

David Dadiomov, PharmD, BCPP Related seminars and products

---

David Dadiomov, PharmD, BCPP, is an assistant professor of clinical pharmacy in the Titus Family Department of Clinical Pharmacy at the USC Mann School of Pharmacy and Pharmaceutical Sciences.

He holds board certification in psychiatric pharmacy and serves as the director of the PGY2 Psychiatric Pharmacy Residency Program. He has led, co-led and conducted extensive research on opioid use disorders among vulnerable populations, prevalence and distribution of high-risk prescription opioid use, therapeutic drug monitoring, treatment-resistant psychiatric conditions and more. Dr. Dadiomov practices as a clinical pharmacy specialist in addiction and psychiatry at the Complex Care Clinic of the Los Angeles County Department of Health Services, one of the largest of its kind in the United States.

Dr. Dadiomov’s teaching approach is case focused, practical for any clinical setting, interactive and evidence supported. His expertise has been shared with experienced clinicians, graduate students and advanced level students. Dr. Dadiomov is the recipient of multiple awards for clinical excellence, teaching and clinical innovation and has presented, authored and co-authored multiple peer-reviewed journal articles, book chapters, and scientific presentations.

 

Speaker Disclosures:
Financial: Dr. David Dadiomov has employment relationships with the University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California Psychiatry and behavioral Sciences Medical Residency, and the Los Angeles County Department of Health Services. He previously received a speaking honorarium from Eli Lilly. Dr. Dadiomov receives grants from the 2024 SC CTSI Standard Pilot Grand Program, the USC Good Neighbors Grant Program, the Southern California Clinical and Translational Sciences Institute, and the Foundation for Opioid Response Efforts. He receives a speaking honorarium and recording royalties from Psychotherapy Networker and PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. David Dadiomov is a member of the American Society of Addiction Medicine, the American Association of Psychiatric Pharmacists, the American College of Clinical Pharmacy, and the American Society of Health-System Pharmacists. He is a reviewer for several publications, for a complete list contact PESI.com.

Additional Info

Access never expires for this product.

For a more detailed outline that includes times or durations of time, if needed, please contact cepesi@pesi.com

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info

Objectives

1. Address misconceptions relating to psychopharmacology that can impact patient care
2. Recognize evidence-based medication prescribing strategies to ensure optimal outcomes
3. Ensure safety of prescribed medications through laboratory, patient assessment, and patient education
4. Identify best counseling points for patient’s taking mental health medications
5. Identify common concerns relating to medications for patients with mental health disorders
6. Improve access to mental health care services 

Outline

• Foundational concepts in psychopharmacology 
  • Drug targets
  • Neurotransmitters involved in treatment
• Differential diagnosis in mental health conditions
  • Substance intoxication or withdrawal
  • Other mental health conditions
  • Other physical health conditions
  • How to screen and rule out other diagnoses
• Practical Psychopharmacology for Depression Treatment
  • SSRIs
  • SNRIs
  • Atypical Antidepressants
  • New treatments
  • Adverse effects
    • Adverse effects that are applicable to the whole class
    • Specific adverse effect management
  • Efficacy of antidepressants and time course
• Practical Psychopharmacology for Anxiety Treatment
  • SSRIs
  • SNRIs
  • Benzodiazepines
  • Buspirone
  • Hydroxyzine
• Practical Psychopharmacology for Schizophrenia Treatment
  • Antipsychotics
    • 1st generation antipsychotics
    • 2nd generation antipsychotics
    • Clozapine
  • Therapeutic drug monitoring
  • Black box warnings
  • Long acting injectable antipsychotics
  • Management of acute agitation
• Practical Psychopharmacology for Bipolar Disorder Treatment
  • Mood stabilizers
    • Lithium
    • Valproic acid
    • Lamotrigine
    • Carbamazepine
    • Second-generation antipsychotics
  • Therapeutic drug monitoring
  • Black box warnings

Pregnancy/lactation warnings

Target Audience

• Addiction Counselors
• Case Managers
• Counselors
• Marriage & Family Therapists
• Nurses
• Pharmacists
• Psychologists
• Social Workers
• other Mental Health Professionals
• other health care professionals
• Physician Assistants
• Nurse Practitioners